Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has earned a consensus rating of “Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $21.33.
Several brokerages recently weighed in on VNDA. BidaskClub cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. Oppenheimer Holdings, Inc. set a $21.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Piper Jaffray Companies set a $23.00 price objective on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. HC Wainwright set a $18.00 price objective on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, Jefferies Group LLC reissued a “buy” rating and set a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, May 25th.
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded up 0.32% on Friday, reaching $15.45. 63,241 shares of the company traded hands. Vanda Pharmaceuticals has a 1-year low of $11.58 and a 1-year high of $18.00. The firm’s market capitalization is $693.06 million. The stock has a 50-day moving average price of $16.17 and a 200 day moving average price of $14.69.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. The firm had revenue of $42.06 million for the quarter, compared to analysts’ expectations of $40.31 million. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The firm’s revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.01 earnings per share. Analysts anticipate that Vanda Pharmaceuticals will post ($0.52) EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. Legal & General Group Plc raised its position in Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 3,022 shares during the period. Virginia Retirement Systems ET AL purchased a new position in Vanda Pharmaceuticals during the first quarter worth $193,000. Capital Fund Management S.A. purchased a new position in Vanda Pharmaceuticals during the first quarter worth $195,000. Dynamic Technology Lab Private Ltd purchased a new position in Vanda Pharmaceuticals during the first quarter worth $196,000. Finally, AQR Capital Management LLC purchased a new position in Vanda Pharmaceuticals during the fourth quarter worth $223,000. Institutional investors and hedge funds own 91.42% of the company’s stock.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.